Detailed Description Of A Highly Potent SARS-CoV-2 Neutralizing Antibody: Bamlanivimab

Monoclonal antibodies have been shown to be effective in both the prevention and early treatment of SARS-CoV-2 infections. One of the antibodies currently approved for clinical use by emergency use authorization is a combination antibody treatment of bamlanivimab and etesevimab. A recent paper by Jones et al. describes bamlanivimab and its properties in detail, as well as details how bamlanivimab was discovered, providing a potential blueprint for antibody discovery in the future.

Monoclonal antibodies are typically laboratory-produced molecules that mimic the adaptive immune system’s response to invading pathogens. They neutralize a virus by blocking the Spike (S) protein from attaching to the host ACE2 receptor, which reduces viral reproduction and immune reactions.

Read the full article on Forbes.

© William A. Haseltine, PhD. All Rights Reserved.